Summary

The global market for Hirudin was estimated to be worth US$ 4223 million in 2024 and is forecast to a readjusted size of US$ 5214 million by 2031 with a CAGR of 3.1% during the forecast period 2025-2031.
This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Hirudin cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.
Hirudin is a potent anticoagulant protein originally derived from the salivary glands of the medicinal leech (Hirudo medicinalis). Its mechanism of action involves directly binding to thrombin, the enzyme responsible for converting fibrinogen into fibrin during the clotting process, thus preventing blood coagulation. This unique property makes hirudin a highly effective anticoagulant, especially in patients at risk of thrombus formation. With the advancement of biotechnology, the production of hirudin has shifted from being sourced directly from leeches to large-scale synthesis through recombinant DNA technology in laboratories. Currently, hirudin is primarily used in the treatment of thrombotic conditions such as deep vein thrombosis (DVT), pulmonary embolism, and certain types of strokes. It is considered an effective alternative for patients who are allergic or intolerant to traditional anticoagulants like heparin. Over the years, with increasing research into hirudin’s applications, various derivatives and related drugs, such as lepirudin and desirudin, have been developed, broadening its clinical use.
The market development of hirudin is driven by several factors. Firstly, the growing global demand for the treatment of thrombotic diseases, particularly among cardiovascular patients and post-surgical individuals, presents significant opportunities for hirudin and its derivatives. With the aging population and the increasing prevalence of thrombotic and vascular diseases, there is a rising demand for effective anticoagulants. Secondly, hirudin's unique mechanism of action offers advantages in treating certain conditions, particularly for patients who are allergic to traditional anticoagulants like heparin, further driving the market for hirudin products.
However, the hirudin market faces challenges and risks. The production cost remains high, particularly in the early stages when biotechnology was not fully developed, limiting its widespread use. Additionally, although hirudin has strong anticoagulant effects, its use requires careful monitoring of the patient's coagulation function to prevent the risk of bleeding.
In terms of market concentration, as production technologies for hirudin mature, the market has become more concentrated in the hands of a few large pharmaceutical companies that maintain their market share through acquisitions, research and development, and patented technologies. The downstream demand trend is diversifying, with hirudin finding applications not only in traditional thrombotic disease treatment but also in other coagulation disorders and post-surgical care. Recent technological advances include the recombinant production of hirudin using genetic engineering, which has significantly improved production efficiency and lowered costs, potentially expanding the use of hirudin in the future.
This report aims to provide a comprehensive presentation of the global market for Hirudin, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Hirudin by region & country, by Type, and by Application.
The Hirudin market size, estimations, and forecasts are provided in terms of sales volume (Tons) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hirudin.
Market Segmentation
By Company
Novartis
Teva Pharmaceuticals
Pfizer, Inc
Pentapharm
DUOPUTAI
Abbott
Keyken
Minapharm
Salubris Bio
Hoechst AG
Ciba-Geigy
Boehringer Ingelheim
Sanofi
Xellia Pharmaceuticals
Haplogen Pharmaceuticals
Shenzhen Kangtai Biological
Dong-A ST
Segment by Type
Natural Hirudin
Recombinant Hirudin
Segment by Application
Thrombosis Disease
Tumor Disease
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Hirudin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Hirudin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Hirudin in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

ページTOPに戻る

Table of Contents

1 Market Overview
1.1 Hirudin Product Introduction
1.2 Global Hirudin Market Size Forecast
1.2.1 Global Hirudin Sales Value (2020-2031)
1.2.2 Global Hirudin Sales Volume (2020-2031)
1.2.3 Global Hirudin Sales Price (2020-2031)
1.3 Hirudin Market Trends & Drivers
1.3.1 Hirudin Industry Trends
1.3.2 Hirudin Market Drivers & Opportunity
1.3.3 Hirudin Market Challenges
1.3.4 Hirudin Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Hirudin Players Revenue Ranking (2024)
2.2 Global Hirudin Revenue by Company (2020-2025)
2.3 Global Hirudin Players Sales Volume Ranking (2024)
2.4 Global Hirudin Sales Volume by Company Players (2020-2025)
2.5 Global Hirudin Average Price by Company (2020-2025)
2.6 Key Manufacturers Hirudin Manufacturing Base and Headquarters
2.7 Key Manufacturers Hirudin Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Hirudin
2.9 Hirudin Market Competitive Analysis
2.9.1 Hirudin Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by Hirudin Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hirudin as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Natural Hirudin
3.1.2 Recombinant Hirudin
3.2 Global Hirudin Sales Value by Type
3.2.1 Global Hirudin Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Hirudin Sales Value, by Type (2020-2031)
3.2.3 Global Hirudin Sales Value, by Type (%) (2020-2031)
3.3 Global Hirudin Sales Volume by Type
3.3.1 Global Hirudin Sales Volume by Type (2020 VS 2024 VS 2031)
3.3.2 Global Hirudin Sales Volume, by Type (2020-2031)
3.3.3 Global Hirudin Sales Volume, by Type (%) (2020-2031)
3.4 Global Hirudin Average Price by Type (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Thrombosis Disease
4.1.2 Tumor Disease
4.1.3 Others
4.2 Global Hirudin Sales Value by Application
4.2.1 Global Hirudin Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Hirudin Sales Value, by Application (2020-2031)
4.2.3 Global Hirudin Sales Value, by Application (%) (2020-2031)
4.3 Global Hirudin Sales Volume by Application
4.3.1 Global Hirudin Sales Volume by Application (2020 VS 2024 VS 2031)
4.3.2 Global Hirudin Sales Volume, by Application (2020-2031)
4.3.3 Global Hirudin Sales Volume, by Application (%) (2020-2031)
4.4 Global Hirudin Average Price by Application (2020-2031)
5 Segmentation by Region
5.1 Global Hirudin Sales Value by Region
5.1.1 Global Hirudin Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Hirudin Sales Value by Region (2020-2025)
5.1.3 Global Hirudin Sales Value by Region (2026-2031)
5.1.4 Global Hirudin Sales Value by Region (%), (2020-2031)
5.2 Global Hirudin Sales Volume by Region
5.2.1 Global Hirudin Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global Hirudin Sales Volume by Region (2020-2025)
5.2.3 Global Hirudin Sales Volume by Region (2026-2031)
5.2.4 Global Hirudin Sales Volume by Region (%), (2020-2031)
5.3 Global Hirudin Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America Hirudin Sales Value, 2020-2031
5.4.2 North America Hirudin Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe Hirudin Sales Value, 2020-2031
5.5.2 Europe Hirudin Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific Hirudin Sales Value, 2020-2031
5.6.2 Asia Pacific Hirudin Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America Hirudin Sales Value, 2020-2031
5.7.2 South America Hirudin Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa Hirudin Sales Value, 2020-2031
5.8.2 Middle East & Africa Hirudin Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Hirudin Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Hirudin Sales Value and Sales Volume
6.2.1 Key Countries/Regions Hirudin Sales Value, 2020-2031
6.2.2 Key Countries/Regions Hirudin Sales Volume, 2020-2031
6.3 United States
6.3.1 United States Hirudin Sales Value, 2020-2031
6.3.2 United States Hirudin Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Hirudin Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Hirudin Sales Value, 2020-2031
6.4.2 Europe Hirudin Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Hirudin Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Hirudin Sales Value, 2020-2031
6.5.2 China Hirudin Sales Value by Type (%), 2024 VS 2031
6.5.3 China Hirudin Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Hirudin Sales Value, 2020-2031
6.6.2 Japan Hirudin Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Hirudin Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Hirudin Sales Value, 2020-2031
6.7.2 South Korea Hirudin Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Hirudin Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Hirudin Sales Value, 2020-2031
6.8.2 Southeast Asia Hirudin Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Hirudin Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Hirudin Sales Value, 2020-2031
6.9.2 India Hirudin Sales Value by Type (%), 2024 VS 2031
6.9.3 India Hirudin Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Novartis
7.1.1 Novartis Company Information
7.1.2 Novartis Introduction and Business Overview
7.1.3 Novartis Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Novartis Hirudin Product Offerings
7.1.5 Novartis Recent Development
7.2 Teva Pharmaceuticals
7.2.1 Teva Pharmaceuticals Company Information
7.2.2 Teva Pharmaceuticals Introduction and Business Overview
7.2.3 Teva Pharmaceuticals Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Teva Pharmaceuticals Hirudin Product Offerings
7.2.5 Teva Pharmaceuticals Recent Development
7.3 Pfizer, Inc
7.3.1 Pfizer, Inc Company Information
7.3.2 Pfizer, Inc Introduction and Business Overview
7.3.3 Pfizer, Inc Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Pfizer, Inc Hirudin Product Offerings
7.3.5 Pfizer, Inc Recent Development
7.4 Pentapharm
7.4.1 Pentapharm Company Information
7.4.2 Pentapharm Introduction and Business Overview
7.4.3 Pentapharm Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Pentapharm Hirudin Product Offerings
7.4.5 Pentapharm Recent Development
7.5 DUOPUTAI
7.5.1 DUOPUTAI Company Information
7.5.2 DUOPUTAI Introduction and Business Overview
7.5.3 DUOPUTAI Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 DUOPUTAI Hirudin Product Offerings
7.5.5 DUOPUTAI Recent Development
7.6 Abbott
7.6.1 Abbott Company Information
7.6.2 Abbott Introduction and Business Overview
7.6.3 Abbott Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Abbott Hirudin Product Offerings
7.6.5 Abbott Recent Development
7.7 Keyken
7.7.1 Keyken Company Information
7.7.2 Keyken Introduction and Business Overview
7.7.3 Keyken Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Keyken Hirudin Product Offerings
7.7.5 Keyken Recent Development
7.8 Minapharm
7.8.1 Minapharm Company Information
7.8.2 Minapharm Introduction and Business Overview
7.8.3 Minapharm Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Minapharm Hirudin Product Offerings
7.8.5 Minapharm Recent Development
7.9 Salubris Bio
7.9.1 Salubris Bio Company Information
7.9.2 Salubris Bio Introduction and Business Overview
7.9.3 Salubris Bio Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 Salubris Bio Hirudin Product Offerings
7.9.5 Salubris Bio Recent Development
7.10 Hoechst AG
7.10.1 Hoechst AG Company Information
7.10.2 Hoechst AG Introduction and Business Overview
7.10.3 Hoechst AG Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 Hoechst AG Hirudin Product Offerings
7.10.5 Hoechst AG Recent Development
7.11 Ciba-Geigy
7.11.1 Ciba-Geigy Company Information
7.11.2 Ciba-Geigy Introduction and Business Overview
7.11.3 Ciba-Geigy Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
7.11.4 Ciba-Geigy Hirudin Product Offerings
7.11.5 Ciba-Geigy Recent Development
7.12 Boehringer Ingelheim
7.12.1 Boehringer Ingelheim Company Information
7.12.2 Boehringer Ingelheim Introduction and Business Overview
7.12.3 Boehringer Ingelheim Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
7.12.4 Boehringer Ingelheim Hirudin Product Offerings
7.12.5 Boehringer Ingelheim Recent Development
7.13 Sanofi
7.13.1 Sanofi Company Information
7.13.2 Sanofi Introduction and Business Overview
7.13.3 Sanofi Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
7.13.4 Sanofi Hirudin Product Offerings
7.13.5 Sanofi Recent Development
7.14 Xellia Pharmaceuticals
7.14.1 Xellia Pharmaceuticals Company Information
7.14.2 Xellia Pharmaceuticals Introduction and Business Overview
7.14.3 Xellia Pharmaceuticals Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
7.14.4 Xellia Pharmaceuticals Hirudin Product Offerings
7.14.5 Xellia Pharmaceuticals Recent Development
7.15 Haplogen Pharmaceuticals
7.15.1 Haplogen Pharmaceuticals Company Information
7.15.2 Haplogen Pharmaceuticals Introduction and Business Overview
7.15.3 Haplogen Pharmaceuticals Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
7.15.4 Haplogen Pharmaceuticals Hirudin Product Offerings
7.15.5 Haplogen Pharmaceuticals Recent Development
7.16 Shenzhen Kangtai Biological
7.16.1 Shenzhen Kangtai Biological Company Information
7.16.2 Shenzhen Kangtai Biological Introduction and Business Overview
7.16.3 Shenzhen Kangtai Biological Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
7.16.4 Shenzhen Kangtai Biological Hirudin Product Offerings
7.16.5 Shenzhen Kangtai Biological Recent Development
7.17 Dong-A ST
7.17.1 Dong-A ST Company Information
7.17.2 Dong-A ST Introduction and Business Overview
7.17.3 Dong-A ST Hirudin Sales, Revenue, Price and Gross Margin (2020-2025)
7.17.4 Dong-A ST Hirudin Product Offerings
7.17.5 Dong-A ST Recent Development
8 Industry Chain Analysis
8.1 Hirudin Industrial Chain
8.2 Hirudin Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Hirudin Sales Model
8.5.2 Sales Channel
8.5.3 Hirudin Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer